Ansbert Gadicke - 13 May 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Reporting relationship: Former 10% Owner
Issuer ticker: ITOS
Reported as of: 13 May 2025
Net transaction value: -$8,317,364
SEC form: 4
Accepted by SEC: 15 May 2025, 17:34:15 UTC
Prior SEC filing: 30 Apr 2025
Next SEC filing: 29 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Ansbert Gadicke

Key filing fact

Ansbert Gadicke filed Form 4 for iTeos Therapeutics, Inc. (ITOS) on 15 May 2025.

Key facts

This page summarizes Ansbert Gadicke's Form 4 filing for iTeos Therapeutics, Inc. (ITOS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 May 2025, 17:34.

Change

Previous filing in this sequence was filed on 30 Apr 2025.
Current net transaction value: -$8,317,364.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (4)

CIK 0001134655 Primary reporting owner

GADICKE ANSBERT

Relationship: Former 10% Owner
Address: C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature: /s/ Ansbert Gadicke
Signature date: 15 May 2025

CIK 0001687078

MPM BioImpact LLC

Relationship: Former 10% Owner
Address: C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature: /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund L.P
Signature date: 15 May 2025

CIK 0001721036

Oncology Impact Fund (Cayman) Management L.P.

Relationship: Former 10% Owner
Address: C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature: /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P.
Signature date: 15 May 2025

CIK 0001691428

UBS Oncology Impact Fund L.P.

Relationship: Former 10% Owner
Address: C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature: /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC
Signature date: 15 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ITOS transaction

Common Stock

Sale

Transaction value: $8,317,364
Shares: -1,031,931
Change %: -23%
Price: $8.06
Shares after: 3,452,797
Date: 13 May 2025
Ownership: See Footnote
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Ansbert Gadicke is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.

Footnote F2

MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.